Articles

As drug companies search for innovative approaches to increase the speed and reduce the cost of drug development, the greatest advances will derive from improved coordination with development partners and enhanced clinical trial design, according to the Tufts Center for the Study of Drug Development (CSDD).

With the addition of everolimus (Afinitor^®) to exemestane, postmenopausal women whose advanced breast cancer no longer responded to hormonal therapy lived approximately 4 months longer without disease progression compared with women who received exemestane alone.

A physical therapist can significantly reduce costs and the need for intensive rehabilitation by diagnosing and treating breast cancer-related lymphedema early, according to an article published in the January issue of Physical Therapy, the scientific journal of the American Physical Therapy Association (APTA).

According to new research, annual prostate cancer screening among men in their 50s and 60s and those with underlying health conditions does not reduce deaths from the disease.

A Phase 3 Trial Comparing Axitinib and Sorafenib in Advanced Renal-Cell Cancer
Read More ›

The use of antiestrogen supplements in women with breast cancer may decrease the risk for melanoma, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

Data from 7360 women with breast cancer between 1980 and 2005 were analyzed by Christine Bouchardy, MD, PhD, professor at the University of Geneva and head of the Geneva Cancer Registry, and colleagues. Antiestrogen therapy was given to 54% of these women.

Recently, the European Commission approved Avastin (bevacizumab) as a front-line treatment for women with advanced ovarian cancer when used in combination with standard chemotherapy.

Approximately 220,000 women are diagnosed and 140,000 women die of ovarian cancer each year globally. Prior to the approval of bevacizumab, ovarian cancer treatment had been limited to surgery and chemotherapy.

The American Cancer Society (ACS) has revised its guideline development process. The new methods align with new principles from the Institutes of Medicine (IOM) by:

When breast cancer patients’ doctors comanage their care with other specialists, the patients report greater satisfaction with their care. However, not all specialists are likely to share decision making with other physicians, according to a new study in Health Services Research.

 “Breast cancer is typically a condition that is managed by multiple specialists. Often a surgeon is involved as well as a medical oncologist, radiologist and primary care physician,” said Katherine Kahn, MD, and senior author of the study.